Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

Human immunodeficiency virus type 1 (HIV-1) Env-, Gag-, Pol-, Nef-, and Tat-specific cytotoxic T-lymphocyte (CTL) activities were quantitated temporally in five patients with symptomatic primary HIV-1 infection. A dominant CD8(+)-mediated, major histocompatibility complex class I-restricted CTL response to the HIV-1 envelope glycoprotein, gp160, was noted in four of the five patients studied. The level of HIV-1-specific CTL activity in the five patients paralleled the efficiency of control of primary viremia. Patients who mounted strong gp160-specific CTL responses showed rapid reduction of acute plasma viremia and antigenemia, while in contrast, primary viremia and antigenemia were poorly controlled in patients in whom virus-specific CTL activity was low or undetectable. These results suggest that HIV-1-specific CTL activity is a major component of the host immune response associated with the control of virus replication following primary HIV-1 infection and have important implications for the design of antiviral vaccines.

[1]  J. Berzofsky,et al.  Exposure to Human Immunodeficiency Virus Type I-Specific T Helper Cell Responses before Detection of Infection by Polymerase Chain Reaction and Serum Antibodies , 1991 .

[2]  M. Oldstone,et al.  Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo , 1984, Journal of virology.

[3]  B. Moss,et al.  Vaccinia VirusExpression Vector: Coexpression of1-Galactosidase Provides Visual Screening ofRecombinant VirusPlaques , 1985 .

[4]  D. Montefiori,et al.  Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques , 1994, Journal of virology.

[5]  B. Walker,et al.  HIV-specific cytotoxic T lymphocytes in seropositive individuals , 1987, Nature.

[6]  B. Moss,et al.  Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein. , 1990, Journal of immunology.

[7]  R. Koup,et al.  Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. , 1989, Blood.

[8]  J. Berzofsky,et al.  Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. , 1992, The Journal of infectious diseases.

[9]  D. Ho,et al.  Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope , 1994, The Journal of experimental medicine.

[10]  P. Earl,et al.  Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses , 1991, Journal of virology.

[11]  P. Earl,et al.  Characterization of human immunodeficiency virus gag/pol gene products expressed by recombinant vaccinia viruses. , 1988, Virology.

[12]  R. Young,et al.  Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. McMichael,et al.  Cytotoxic T-cell immunity to influenza. , 1983, The New England journal of medicine.

[14]  M. Merson,et al.  Slowing the spread of HIV: agenda for the 1990s. , 1993, Science.

[15]  B. Moss,et al.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques , 1985, Molecular and cellular biology.

[16]  K. Ariyoshi,et al.  Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies? , 1992, The Lancet.

[17]  P. Earl,et al.  Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. J. Clark,et al.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.

[19]  K. Nagashima,et al.  Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[20]  B. Guy,et al.  Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins , 1989, Journal of virology.

[21]  B. Autran,et al.  Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. , 1989, Journal of immunology.

[22]  D. Nixon,et al.  Cytotoxic T-cell recognition of HIV proteins and peptides. , 1991, AIDS.

[23]  J. Weber,et al.  Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. , 1991, British medical journal.

[24]  T. Masuda,et al.  Interference with human immunodeficiency virus (HIV) replication by CD8+ T cells in peripheral blood leukocytes of asymptomatic HIV carriers in vitro , 1990, Journal of virology.

[25]  C. Mims,et al.  Viral Pathogenesis and Immunology , 1984 .

[26]  G. Ada,et al.  Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus , 1978, Nature.

[27]  Charles R. M. Bangham,et al.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition , 1991, Nature.

[28]  B. Walker,et al.  Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation , 1992, The Journal of experimental medicine.

[29]  D. Ho,et al.  Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. , 1991, The New England journal of medicine.

[30]  B. Walker,et al.  Cytotoxic T lymphocytes against HIV. , 1990, AIDS.

[31]  D. Tyler,et al.  GP120 specific cellular cytotoxicity in HIV-1 seropositive individuals. Evidence for circulating CD16+ effector cells armed in vivo with cytophilic antibody. , 1989, Journal of immunology.

[32]  N. Letvin,et al.  Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys , 1993, Journal of virology.

[33]  D. Watkins,et al.  A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. , 1989, Disease markers.

[34]  B. Moss,et al.  Use of vaccinia virus vectors to study the synthesis, intracellular localization, and action of the human immunodeficiency virus trans-activator protein. , 1988, Virology.

[35]  J. Levy,et al.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. , 1986, Science.

[36]  P. Earl,et al.  Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus , 1990, Journal of virology.

[37]  K. Schneweis,et al.  Protection of mice from fatal herpes simplex virus type 1 infection by adoptive transfer of cloned virus-specific and H-2-restricted cytotoxic T lymphocytes. , 1983, The Journal of general virology.

[38]  J. Claverie,et al.  T‐immunogenic peptides are constituted of rare sequence patterns. Use in the identification of T epitopes in the human immunodeficiency virus gag protein , 1988, European journal of immunology.

[39]  B. Autran,et al.  AIDS virus-specific cytotoxic T lymphocytes in lung disorders , 1987, Nature.

[40]  A. Régnault,et al.  Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV‐1 by deletion of the env amino‐terminal signal sequence , 1990, European journal of immunology.

[41]  P. Greenberg,et al.  Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  B. Moss,et al.  An HLA-C-restricted CD8+ cytotoxic T-lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag , 1991, Journal of virology.